ClinicalTrials.gg
CompletedNCT00628251ICEBERG 3Updated Dec 5, 2019Results posted

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

A Phase 2 interventional study of AZD2281 and Liposomal Doxorubicin in Ovarian Neoplasms, sponsored by AstraZeneca. Completed at 24 sites in 9 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-12-05.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
34th of 69
97 · median 96
Started
2008
with 3 others
Phase 2
32 of 69
7 open now
Registered
4th of 69
by date
Lead sponsor
21 of 69
AstraZeneca

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 34th largest by enrollment, is one of 4 that started in 2008, is one of 32 in phase 2, and was the 4th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 130 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.

03

Conditions studied

  • Ovarian Neoplasms

Keywords

  • Advanced ovarian cancer
  • BRCA1 protein
  • BRCA2 protein
  • Poly(ADP ribose) polymerases
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced ovarian cancer with positive BRCA1 or BRCA2 status
  • Progressive or recurrent disease after platinum-based chemotherapy
  • by

Exclusion criteria

Exclusion Criteria:

  • Previous anthracycline treatment
  • Less than 28 days since last treatment used to treat the disease
  • Considered a poor medical risk due to a serious uncontrolled disorder
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    1

    AZD2281 Oral 200 mg BID

    Drug: AZD2281

  • Active comparator
    2

    Liposomal Doxorubicin

    Drug: Liposomal Doxorubicin

  • Experimental
    3

    AZD2281 Oral 400 mg BID

    Drug: AZD2281

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time to progression from the date of randomisation until the date of radiological assessment of progression per RECIST criteria or death (by any cause in the absence of progression)

    Time frame: Tumour assessment was to be assessed at screening, every 8 weeks during the study and at the withdrawal visit, up to 56 weeks. (Data cut-off for primary analysis of PFS: 15 September 2009)

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined according to RECIST. Complete response (CR) or partial response - (PR)- 30% decrease Patients with a best RECIST response of CR or PR had to have a confirmed response at least 28 days later.

    Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)

  2. Disease Control Rate

    The number of patients with confirmed CR (disappearance of all target lesions) or PR (30% decrease in the sum of the longest diameter of target lesions ) or SD ( small changes ) \>4 months, divided by the number of randomised patients

    Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)

  3. Overall Duration of Response

    The duration of response was defined as time (months) from initial assessment of PR/CR until earliest date of objective progression or death. (Values may be underestimated as some patients had not progressed at final analysis so true duration is likely to be greater than that in database.)

    Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)

  4. Best Percentage Change in Tumour Size

    The percentage change (reduction) from baseline in the sum of the lengths of the longest diameter (LD) of the RECIST target lesions were objectively documented, regardless of whether the patient was still taking study medication

    Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)

  5. Best Percentage Change From Baseline in CA-125 Levels

    Best percentage change in cancer antigen 125 (CA-125) levels

    Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)

  6. Confirmed RECIST Response and/or CA-125 Response

    The percentage of patients reporting a RECIST confirmed response and/or a CA-125 response (in the absence of progression). A CA-125 response was defined as a confirmed greater or equal to 50% reduction in CA-125.

    Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)

  7. Overall Survival (OS)

    OS was defined as time from randomisation to date of death from any cause. Patients who had not died at time of analysis were censored at last date they were known to be alive. Median OS was not calculable for olaparib groups due to an insufficient number of deaths so the percentage of participants who died are shown along with 95% confidence intervals

    Time frame: At the time of the cut-off for the final analysis of overall survival (30 April 2010)

  8. Best Quality of Life (QoL) Response for Trial Outcome Index (TOI)

    Best HRQoL response using the TOI endpoint. Improvement was defined as a change from baseline of greater than or equal to +7. The TOI score ranges from 0-100.

    Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)

  9. Best QoL Response for Total Functional Analysis of Cancer Therapy - Ovarian (FACT-O)

    Best HRQoL response using the total FACT-O endpoint. Improvement was defined as a change from baseline of greater than or equal to +9.

    Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)

  10. Best QoL Response for FACT-O Symptom Index (FOSI)

    Best HRQoL response using the FOSI endpoint. Improvement was defined as a change from baseline of greater than or equal to +3.

    Time frame: At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)

07

Results

Posted Jun 3, 2016
Limitations and caveats
The AEs reported include all events up to the OS data cut-off. After the PFS data cut-off, AEs were only collected for the olaparib and cross-over groups. The safety profile of these 2 groups at OS was consistent with that at the time of PFS.

Participant flow

First patient enrolled on 30 July 2008 and last patient on 3 March 2009 at 25 centres in 9 countries

Randomised Part
Participant flow — Randomised Part
MilestoneOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Started323233
Completed323232
Not completed001
Withdrew: Withdrawal by subject001
Ongoing Initial Study Treatment at DCO
Participant flow — Ongoing Initial Study Treatment at DCO
MilestoneOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Started323232
Discontinued initial study treatment222025
Crossover to olaparib0014
Ongoing crossover at dco005
Discontinued crossover009
Completed10127
Not completed222025
Withdrew: Adverse event123
Withdrew: Condition under investigation worsened191513
Withdrew: Withdrawal by subject121
Withdrew: Other reason016
Withdrew: Other102

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the time to progression from the date of randomisation until the date of radiological assessment of progression per RECIST criteria or death (by any cause in the absence of progression)

Time frame:
Tumour assessment was to be assessed at screening, every 8 weeks during the study and at the withdrawal visit, up to 56 weeks. (Data cut-off for primary analysis of PFS: 15 September 2009)
Reported as:
Count of participants · Participants
Progression Free Survival (PFS)
ParticipantsOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Progression Free Survival (PFS)192020
Statistical analysis
  • Olaparib 200 mg bd vs Olaparib 400 mg bd vs Liposomal Doxorubicin · Regression, Cox · p = 0.6604 (If the observed p-value for the combined olaparib groups is \<0.02 (1-sided) then the result will be regarded as statistically significant.) · Hazard ratio (hr): 0.88 · 95% CI 0.51 to 1.56Cox proportional hazards model with factors for treatment, BRCA (1 or 2) and platinum sensitivity (sensitive=1 or resistant/refractory=0).
  • Olaparib 200 mg bd vs Liposomal Doxorubicin · Regression, Cox · p = 0.7794 (An observed p-value of \<0.005 (1-sided) will be regarded as statistically significant for a given pairwise comparison.) · Hazard ratio (hr): 0.91 · 95% CI 0.48 to 1.74Cox proportional hazards model with factors for treatment, BRCA (1 or 2) and platinum sensitivity (sensitive=1 or resistant/refractory=0).
  • Olaparib 400 mg bd vs Liposomal Doxorubicin · Regression, Cox · p = 0.6604 (An observed p-value of \<0.005 (1-sided) will be regarded as statistically significant for a given pairwise comparison.) · Hazard ratio (hr): 0.86 · 95% CI 0.45 to 1.62Cox proportional hazards model with factors for treatment, BRCA (1 or 2) and platinum sensitivity (sensitive=1 or resistant/refractory=0).
SecondaryObjective Response Rate (ORR)

ORR was defined according to RECIST. Complete response (CR) or partial response - (PR)- 30% decrease Patients with a best RECIST response of CR or PR had to have a confirmed response at least 28 days later.

Time frame:
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Complete response000
Number of Partial responders8106
Statistical analysis
  • Olaparib 200 mg bd vs Olaparib 400 mg bd vs Liposomal Doxorubicin · Regression, Logistic · p = 0.1291 (2-sided p-value) · Odds ratio (or): 2.27 · 95% CI 0.79 to 7.32An odds ratio \>1 favoured olaparib
  • Olaparib 200 mg bd vs Liposomal Doxorubicin · Regression, Logistic · p = 0.3131 (2-sided p-value) · Odds ratio (or): 1.90 · 95% CI 0.55 to 7.01An odds ratio \>1 favoured olaparib.
  • Olaparib 400 mg bd vs Liposomal Doxorubicin · Regression, Logistic · p = 0.1079 · Odds ratio (or): 2.69 · 95% CI 0.81 to 9.76An odds ratio \>1 favoured olaparib
SecondaryDisease Control Rate

The number of patients with confirmed CR (disappearance of all target lesions) or PR (30% decrease in the sum of the longest diameter of target lesions ) or SD ( small changes ) \>4 months, divided by the number of randomised patients

Time frame:
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Reported as:
Count of participants · Participants
Disease Control Rate
ParticipantsOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Disease Control Rate212119
SecondaryOverall Duration of Response

The duration of response was defined as time (months) from initial assessment of PR/CR until earliest date of objective progression or death. (Values may be underestimated as some patients had not progressed at final analysis so true duration is likely to be greater than that in database.)

Time frame:
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Reported as:
Median · Months
Overall Duration of Response
MonthsOlaparib 200 mg bdOlaparib 400 mg bdOlaparib 200 mg bd + Olaparib 400 mg bd,Liposomal Doxorubicin
Overall Duration of Response5.95 (3.71 to NA)6.80 (5.52 to 7.39)6.24 (5.52 to 7.39)5.49 (4.67 to 9.13)
SecondaryBest Percentage Change in Tumour Size

The percentage change (reduction) from baseline in the sum of the lengths of the longest diameter (LD) of the RECIST target lesions were objectively documented, regardless of whether the patient was still taking study medication

Time frame:
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Reported as:
Median · Percent change
Best Percentage Change in Tumour Size
Percent changeOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Best Percentage Change in Tumour Size-15.90 (-75.30 to 31.48)-24.60 (-100.00 to 51.10)-14.3 (-87.5 to 32.4)
SecondaryBest Percentage Change From Baseline in CA-125 Levels

Best percentage change in cancer antigen 125 (CA-125) levels

Time frame:
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Reported as:
Median · Percent change
Best Percentage Change From Baseline in CA-125 Levels
Percent changeOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Best Percentage Change From Baseline in CA-125 Levels-37.42 (-98.77 to 327.76)-71.19 (-96.88 to 70.56)-55.8 (-99.5 to 192.1)
SecondaryConfirmed RECIST Response and/or CA-125 Response

The percentage of patients reporting a RECIST confirmed response and/or a CA-125 response (in the absence of progression). A CA-125 response was defined as a confirmed greater or equal to 50% reduction in CA-125.

Time frame:
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Reported as:
Number · Percentage of participants
Confirmed RECIST Response and/or CA-125 Response
Percentage of participantsOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Confirmed RECIST Response and/or CA-125 Response37.559.439.4
SecondaryOverall Survival (OS)

OS was defined as time from randomisation to date of death from any cause. Patients who had not died at time of analysis were censored at last date they were known to be alive. Median OS was not calculable for olaparib groups due to an insufficient number of deaths so the percentage of participants who died are shown along with 95% confidence intervals

Time frame:
At the time of the cut-off for the final analysis of overall survival (30 April 2010)
Reported as:
Count of participants · Participants
Overall Survival (OS)
ParticipantsOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Overall Survival (OS)91113
Statistical analysis
  • Olaparib 200 mg bd vs Olaparib 400 mg bd vs Liposomal Doxorubicin · Regression, Cox · p = 0.5781 (2-sided p-value) · Hazard ratio (hr): 0.82 · 95% CI 0.41 to 1.70A hazard ratio of \<1 favoured olaparib.
  • Olaparib 200 mg bd vs Liposomal Doxorubicin · Regression, Cox · p = 0.3417 (2-sided p-value) · Hazard ratio (hr): 0.66 · 95% CI 0.27 to 1.55A hazard ratio of \<1 favoured olaparib.
  • Olaparib 400 mg bd vs Liposomal Doxorubicin · Regression, Cox · p = 0.9877 (2-sided p-value) · Hazard ratio (hr): 1.01 · 95% CI 0.44 to 2.27A hazard ratio of \<1 favoured olaparib.
SecondaryBest Quality of Life (QoL) Response for Trial Outcome Index (TOI)

Best HRQoL response using the TOI endpoint. Improvement was defined as a change from baseline of greater than or equal to +7. The TOI score ranges from 0-100.

Time frame:
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Reported as:
Count of participants · Participants
Best Quality of Life (QoL) Response for Trial Outcome Index (TOI)
ParticipantsOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Improved753
No change101011
Worsened376
Non-evaluable577
SecondaryBest QoL Response for Total Functional Analysis of Cancer Therapy - Ovarian (FACT-O)

Best HRQoL response using the total FACT-O endpoint. Improvement was defined as a change from baseline of greater than or equal to +9.

Time frame:
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Reported as:
Count of participants · Participants
Best QoL Response for Total Functional Analysis of Cancer Therapy - Ovarian (FACT-O)
ParticipantsOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Improved361
No Change141111
Worsened357
Non-evaluable578
SecondaryBest QoL Response for FACT-O Symptom Index (FOSI)

Best HRQoL response using the FOSI endpoint. Improvement was defined as a change from baseline of greater than or equal to +3.

Time frame:
At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)
Reported as:
Count of participants · Participants
Best QoL Response for FACT-O Symptom Index (FOSI)
ParticipantsOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Improved543
No change14910
Worsened197
Non-evaluable577
PrimaryProgression Free Survival (PFS)

PFS was defined as the time to progression from the date of randomisation until the date of radiological assessment of progression per RECIST criteria or death (by any cause in the absence of progression)

Time frame:
Tumour assessment was to be assessed at screening, every 8 weeks during the study and at the withdrawal visit, up to 56 weeks. (Data cut-off for primary analysis of PFS: 15 September 2009)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Progression Free Survival (PFS)6.5 (5.5 to 10.1)8.8 (5.4 to 9.2)7.1 (3.7 to 10.7)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib 200 mg bd—5/32 (15.6%)32/32 (100%)
Olaparib 400 mg bd—6/32 (18.8%)32/32 (100%)
Liposomal Doxorubicin—5/32 (15.6%)31/32 (96.9%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
Cerebrovascular AccidentNervous system disorders2/320/320/32
VomitingGastrointestinal disorders0/320/321/32
Abdominal Pain LowerGastrointestinal disorders0/320/321/32
ConstipationGastrointestinal disorders1/320/320/32
Intestinal ObstructionGastrointestinal disorders1/321/320/32
NauseaGastrointestinal disorders0/320/321/32
Small Intestinal ObstructionGastrointestinal disorders0/321/320/32
SubileusGastrointestinal disorders0/321/320/32
FatigueGeneral disorders1/320/321/32
PyrexiaGeneral disorders0/321/320/32
Most frequent other events
Showing 10 of 84
Most frequent other events
EventOlaparib 200 mg bdOlaparib 400 mg bdLiposomal Doxorubicin
NauseaGastrointestinal disorders19/3225/3218/32
FatigueGeneral disorders12/3221/3214/32
Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders0/320/3220/32
StomatitisGastrointestinal disorders0/321/3219/32
VomitingGastrointestinal disorders11/3216/3210/32
RashSkin and subcutaneous tissue disorders3/323/3214/32
Abdominal PainGastrointestinal disorders12/328/3212/32
ConstipationGastrointestinal disorders9/326/3212/32
DiarrhoeaGastrointestinal disorders8/3212/3210/32
AnaemiaBlood and lymphatic system disorders4/3211/322/32

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Olaparib 200 mg bdOlaparib 400 mg bdLiposomal DoxorubicinTotal
Mean57.2 ± 8.5353.8 ± 8.7754.3 ± 9.3255.5 ± 8.92
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib 200 mg bdOlaparib 400 mg bdLiposomal DoxorubicinTotal
Female32323397
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Olaparib 200 mg bdOlaparib 400 mg bdLiposomal DoxorubicinTotal
African-Caribbean0011
Ashkenazi Jewish8101129
Sephardic Jewish0022
Not applicable20211960
Other4105
BRCA status
BRCA status(Participants)Olaparib 200 mg bdOlaparib 400 mg bdLiposomal DoxorubicinTotal
Deleterious BRCA1 mutation26282781
Deleterious BRCA2 mutation64616
08

Study locations

24 sites
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    San Francisco, California 94115, United States
  • Research Site
    Boca Raton, Florida 33428, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    East Melbourne, 3002, Australia
  • Research Site
    Melbourne, Parkville, VIC 3050, Australia
  • Research Site
    Randwick, 2031, Australia
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Köln, 50937, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Ramat Gan, 52621, Israel
  • Research Site
    Tel Aviv, 6423906, Israel
  • Research Site
    Szczecin, 70-111, Poland
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Hospitalet deLlobregat, 08907, Spain
  • Research Site
    Lund, 22185, Sweden
  • Research Site
    Cambridge, CB2 0QQ, United Kingdom
  • Research Site
    Edinburgh, EH4 2XR, United Kingdom
  • Research Site
    London, SE1 9RT, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. PubMed 35170751 ↗
  • Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidzinski M, Kim JW, Nam JH, Madry R, Hernandez C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol. 2020 Apr 10;38(11):1164-1174. doi: 10.1200/JCO.19.02745. Epub 2020 Feb 19. PubMed 32073956 ↗
  • Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol. 2016 Jun;27(6):1013-1019. doi: 10.1093/annonc/mdw133. Epub 2016 Mar 8. PubMed 26961146 ↗
  • Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6. PubMed 23922302 ↗
  • Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009 Mar;9(3):167-81. doi: 10.1038/nrc2583. PubMed 19238149 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2008 to primary completion in Sep 2009, 13 months.

Results were first posted in Jun 2016, 6 years 8 months after primary completion. A results delay was requested in Jul 2013.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 13 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2008
First posted
Mar 5, 2008
StartActual
Jul 30, 2008
Primary completionActual
Sep 15, 2009
CompletionActual
Sep 19, 2018
Results delay requested
Jul 22, 2013
Results first posted
Jun 3, 2016
Last update
Dec 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00628251
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 5, 2008
Start date
Jul 30, 2008
Primary completion
Sep 15, 2009
Completion
Sep 19, 2018
Results posted
Jun 3, 2016
Last update
Dec 5, 2019

Study contacts

Jane Robertson, BSc, MBCHB, MD
study director · AstraZeneca
Stan Kaye, BSc, MB, FRCP, FRCR, SMedSCi
principal investigator · Royal Marsden NHS Foundation Trust

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion